|IRICoR - Institute for Research in Immunology and Cancer-Commercialization of Research||Vice President, Business Development||Canada|
WHAT ARE THE RECENT INITIATIVES TO DE-RISK ASSETS OF ACADEMIC ORIGIN?
Dr. Steven Klein is Vice-President, Business Development at IRICoR, where he brings over 15 years of business development experience in a variety of fields, including oncology, vaccines, and CNS-related indications. Prior to joining IRICoR, Dr. Klein held Business Development roles at Labopharm, BELLUS Health, Neurochem, the Canadian Network for Vaccines and Immunotherapeutics (CANVAC), and Vasogen.
During his career, Dr. Klein has negotiated and concluded a wide range of licensing and co-development agreements with industry leaders such as Bristol-Myers Squibb, Pfizer, Merck, Roche, GSK, Domain Therapeutics, Encycle Therapeutics, Nippon Shinyaku, Grunenthal, and Sanofi Pasteur. He has also served as acting CEO of ExCellThera, and played a key role in the creation of SpecificiT, two cell therapy companies recently spun out of IRICoR.
Dr Klein holds a B.Sc. (Honors) in Chemistry from Concordia University, a Ph.D. in Experimental Medicine from McGill University, and an MBA from Queen’s University. Dr. Klein is a Board member of the Centre for the Commercialization of Antibodies and Biologics (Toronto, Canada).